Legend Biotech disclosed early findings from an investigator-initiated study of its in vivo CAR-T approach in lymphoma, reporting response activity across the initial cohort. The company said the therapy reduced or eliminated disease signs in all recipients, a preliminary signal that the in vivo design may translate into clinical efficacy. The in vivo platform is positioned as an alternative to ex vivo CAR-T manufacturing by aiming to engineer T cells inside the body rather than producing them externally. In lymphoma, where CAR-T demand is high but manufacturing complexity is a barrier, first-in-human outcomes are closely watched. The report adds pressure to the competitive CAR-T landscape, where investors track whether in vivo approaches can match ex vivo results in durability, toxicity profile, and scalability. Legend’s early dataset may also influence what trial design elements move forward for larger studies. While the data remain preliminary, the announcement underscores that in vivo CAR-T programs are transitioning from concept to measurable clinical outcomes.